KROS Financials Keros Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $244M | $87M | 0.0% | 27.7% | $106M | — | $287M |
| 2024 | $4M | -$187M | 0.0% | -5939.0% | -$163M | — | $560M |
| 2023 | $151000 | -$153M | 0.0% | -112543.7% | -$127M | — | $331M |
| 2022 | $0 | -$105M | — | — | -$71M | — | $279M |
| 2021 | $20M | -$59M | 0.0% | -280.5% | -$63M | — | $230M |
| 2020 | $0 | -$45M | — | — | -$37M | — | $266M |
| 2019 | $10M | -$12M | 0.0% | -105.6% | -$16M | — | $7M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $367000 | -$24M | 0.0% | -7051.0% | -$4M | — | $281M |
| Dec '25 | $385000 | -$23M | 0.0% | -7602.6% | -$27M | — | $287M |
| Sep '25 | $14M | -$7M | 0.0% | -107.9% | $3M | — | $693M |
| Jun '25 | $18M | -$31M | 0.0% | -219.2% | -$30M | — | $690M |
| Mar '25 | $211M | $148M | 0.0% | 72.0% | $161M | — | $721M |
| Dec '24 | $3M | -$46M | 0.0% | -1750.6% | -$46M | — | $560M |
| Sep '24 | $388000 | -$53M | 0.0% | -15117.8% | -$31M | — | $531M |
| Jun '24 | $37000 | -$45M | 0.0% | -136321.6% | -$40M | — | $406M |
| Mar '24 | $83000 | -$43M | 0.0% | -58413.3% | -$46M | — | $442M |
| Dec '23 | $143000 | -$40M | 0.0% | -32486.0% | -$26M | — | $331M |
| Sep '23 | $8000 | -$39M | 0.0% | -541000.0% | -$35M | — | $288M |
| Jun '23 | $0 | -$38M | — | — | -$31M | — | $322M |
| Mar '23 | $0 | -$36M | — | — | -$35M | — | $351M |
| Dec '22 | $0 | -$30M | — | — | -$22M | — | $279M |
| Sep '22 | $0 | -$24M | — | — | -$25M | — | $239M |
| Jun '22 | $0 | -$27M | — | — | -$23M | — | $216M |
| Mar '22 | — | -$24M | — | — | -$2M | — | $229M |
| Dec '21 | $20M | -$7M | 0.0% | -24.3% | -$20M | — | $230M |
| Sep '21 | $0 | -$20M | — | — | -$15M | — | $221M |
| Jun '21 | $100000 | -$16M | 0.0% | -15541.0% | -$18M | — | $237M |
Valuation over time
How the market has priced KROS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 4.6× (Dec '25) to 2.4× (Jun '26).
- The price-to-sales ratio has fallen from 7254.8× (Jan '24) to 0.8× (Jun '26).
Frequently asked questions
Is KROS growing its revenue and profit?
See the revenue and net-income charts above for Keros Therapeutics, Inc.'s multi-year trend.
How much debt does KROS have?
As of FY2025, Keros Therapeutics, Inc. reported — of total debt against $287M of cash.
What is KROS's profit margin?
In FY2025, gross margin was —, operating margin 27.7%, and net margin 35.7%.
What is KROS's P/E ratio?
As of Jun '26, Keros Therapeutics, Inc. traded at a price-to-earnings ratio of about 2.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.